Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Canaccord's 43rd Annual Growth conference

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Aug 10, 2023 12:12pm

100 Views

Post# 35581935

RE:RE:Canaccord's 43rd Annual Growth conference

We are standing at 50 cents pre-reverse and 45M market cap for an 85M sales company with 2 drugs in the pipeline. The 400M accrued losses are worth 120M in tax savings to a canadian acquirer. I think we can speculate on all the possible negatives in the world since they are piced in a multiple of times thanks to a completly indifferent and unscrupulous seller.

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December